Microplate Dx are an award winning spinout company from the University of Strathclyde in Glasgow, specialising in developing novel diagnostic solutions to tackle the major global health threat of antimicrobial resistance. The Microplate Dx technology is based on the simple yet highly innovative concept of using highly sensitive biosensor electrodes, modified with miniaturised hydrogel deposits laden with different antibiotics, depending on the infection type being measured. Microplate Dx’s mission is to eliminate ‘best-guess’ antibiotic prescribing through our rapid and accurate antibiotic susceptibility tests, vastly reducing deaths.
To date, Microplate Dx has raised close to £1M in private equity investment, non-dilutive grant funding and competition wins. A recent clinical feasibility study performed in collaboration with the NHS has shown successful detection of the optimum antibiotic for an infection in well under an hour. We are now working to scale up our first product for difficult-to-treat urinary tract infections, before expanding our platform capabilities into new infectious disease areas of significant clinical need.
